-
2
-
-
84881619821
-
Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy
-
Crawford S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol 2013, 4:68.
-
(2013)
Front. Pharmacol
, vol.4
, pp. 68
-
-
Crawford, S.1
-
3
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
4
-
-
84884305330
-
Metronomic therapy: chemotherapy revisited
-
Noronha V., Krishna M.V., Patil V., Joshi A., Banavali S.D., Prabhash K. Metronomic therapy: chemotherapy revisited. Indian J. Cancer 2013, 50:142-148.
-
(2013)
Indian J. Cancer
, vol.50
, pp. 142-148
-
-
Noronha, V.1
Krishna, M.V.2
Patil, V.3
Joshi, A.4
Banavali, S.D.5
Prabhash, K.6
-
5
-
-
77955172181
-
Metronomic chemotherapy: new rationale for new directions
-
Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol 2010, 7:455-465.
-
(2010)
Nat. Rev. Clin. Oncol
, vol.7
, pp. 455-465
-
-
Pasquier, E.1
Kavallaris, M.2
Andre, N.3
-
6
-
-
84877850988
-
Center of cancer systems biology second annual workshop - tumor metronomics: timing and dose level dynamics
-
Hahnfeldt P., Hlatky L., Klement G.L. Center of cancer systems biology second annual workshop - tumor metronomics: timing and dose level dynamics. Cancer Res 2013, 73:2949-2954.
-
(2013)
Cancer Res
, vol.73
, pp. 2949-2954
-
-
Hahnfeldt, P.1
Hlatky, L.2
Klement, G.L.3
-
7
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
-
(2000)
Cancer Res
, vol.60
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kraling, B.M.3
Shi, B.4
Marshall, B.5
O'Reilly, M.S.6
-
8
-
-
2542539735
-
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
-
Emmenegger U., Man S., Shaked Y., Francia G., Wong J.W., Hicklin D.J., et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004, 64:3994-4000.
-
(2004)
Cancer Res
, vol.64
, pp. 3994-4000
-
-
Emmenegger, U.1
Man, S.2
Shaked, Y.3
Francia, G.4
Wong, J.W.5
Hicklin, D.J.6
-
9
-
-
84877872854
-
Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells
-
Pasquier E., Tuset M.P., Street J., Sinnappan S., MacKenzie K.L., Braguer D., et al. Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 2013, 16:373-386.
-
(2013)
Angiogenesis
, vol.16
, pp. 373-386
-
-
Pasquier, E.1
Tuset, M.P.2
Street, J.3
Sinnappan, S.4
MacKenzie, K.L.5
Braguer, D.6
-
10
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest 2000, 105:R15-R24.
-
(2000)
J. Clin. Invest
, vol.105
, pp. R15-R24
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.J.6
-
11
-
-
0037093209
-
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
-
Man S., Bocci G., Francia G., Green S.K., Jothy S., Hanahan D., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002, 62:2731-2735.
-
(2002)
Cancer Res
, vol.62
, pp. 2731-2735
-
-
Man, S.1
Bocci, G.2
Francia, G.3
Green, S.K.4
Jothy, S.5
Hanahan, D.6
-
12
-
-
84858799883
-
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
-
Penel N., Adenis A., Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. Crit. Rev. Oncol. Hematol 2012, 82:40-50.
-
(2012)
Crit. Rev. Oncol. Hematol
, vol.82
, pp. 40-50
-
-
Penel, N.1
Adenis, A.2
Bocci, G.3
-
13
-
-
84901001797
-
Metronomics as maintenance treatment in oncology: time for chemo-switch
-
Malik P.S., Raina V., Andre N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front. Oncol 2014, 4:76.
-
(2014)
Front. Oncol
, vol.4
, pp. 76
-
-
Malik, P.S.1
Raina, V.2
Andre, N.3
-
14
-
-
84885179445
-
Low-dose metronomic chemotherapy: a systematic literature analysis
-
Lien K., Georgsdottir S., Sivanathan L., Chan K., Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur. J. Cancer 2013, 49:3387-3395.
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 3387-3395
-
-
Lien, K.1
Georgsdottir, S.2
Sivanathan, L.3
Chan, K.4
Emmenegger, U.5
-
15
-
-
85027957593
-
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
-
Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol 2011, 33:369-383.
-
(2011)
Semin. Immunopathol
, vol.33
, pp. 369-383
-
-
Sistigu, A.1
Viaud, S.2
Chaput, N.3
Bracci, L.4
Proietti, E.5
Zitvogel, L.6
-
16
-
-
79953188695
-
DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity
-
Guerriero J.L., Ditsworth D., Catanzaro J.M., Sabino G., Furie M.B., Kew R.R., et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J. Immunol 2011, 186:3517-3526.
-
(2011)
J. Immunol
, vol.186
, pp. 3517-3526
-
-
Guerriero, J.L.1
Ditsworth, D.2
Catanzaro, J.M.3
Sabino, G.4
Furie, M.B.5
Kew, R.R.6
-
17
-
-
79953821616
-
Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma
-
Maglioco A., Machuca D., Mundinano J., Cabrera G., Camicia G., Bruzzo J., et al. Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma. Cancer Immunol. Immunother 2011, 60:389-399.
-
(2011)
Cancer Immunol. Immunother
, vol.60
, pp. 389-399
-
-
Maglioco, A.1
Machuca, D.2
Mundinano, J.3
Cabrera, G.4
Camicia, G.5
Bruzzo, J.6
-
18
-
-
77958605473
-
Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model
-
Sharabi A., Laronne-Bar-On A., Meshorer A., Haran-Ghera N. Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev. Res. (Phila.) 2010, 3:1265-1276.
-
(2010)
Cancer Prev. Res. (Phila.)
, vol.3
, pp. 1265-1276
-
-
Sharabi, A.1
Laronne-Bar-On, A.2
Meshorer, A.3
Haran-Ghera, N.4
-
20
-
-
70349170354
-
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth
-
van der Most R.G., Currie A.J., Cleaver A.L., Salmons J., Nowak A.K., Mahendran S., et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 2009, 4:e6982.
-
(2009)
PLoS ONE
, vol.4
-
-
van der Most, R.G.1
Currie, A.J.2
Cleaver, A.L.3
Salmons, J.4
Nowak, A.K.5
Mahendran, S.6
-
21
-
-
84857723974
-
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression
-
Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012, 72:1103-1115.
-
(2012)
Cancer Res
, vol.72
, pp. 1103-1115
-
-
Doloff, J.C.1
Waxman, D.J.2
-
22
-
-
84900395848
-
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression
-
Chen C.S., Doloff J.C., Waxman D.J. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014, 16:84-96.
-
(2014)
Neoplasia
, vol.16
, pp. 84-96
-
-
Chen, C.S.1
Doloff, J.C.2
Waxman, D.J.3
-
23
-
-
0021953807
-
In vivo modulation of myelopoiesis and immune functions by maleic anhydride divinyl ether copolymer (MVE-2) in tumor-free and MBL-2 tumor-bearing mice treated with cyclophosphamide
-
Schlick E., Ruffmann R., Chirigos M.A., Welker R.D., Herberman R.B. In vivo modulation of myelopoiesis and immune functions by maleic anhydride divinyl ether copolymer (MVE-2) in tumor-free and MBL-2 tumor-bearing mice treated with cyclophosphamide. Cancer Res 1985, 45:1108-1114.
-
(1985)
Cancer Res
, vol.45
, pp. 1108-1114
-
-
Schlick, E.1
Ruffmann, R.2
Chirigos, M.A.3
Welker, R.D.4
Herberman, R.B.5
-
24
-
-
0023013658
-
Repair processes of hemopoiesis after applying cyclophosphamide. I. Morphological changes in the bone marrow, spleen and thymus
-
Mackova N., Suliova J. Repair processes of hemopoiesis after applying cyclophosphamide. I. Morphological changes in the bone marrow, spleen and thymus. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch 1986, 113:596-604.
-
(1986)
Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch
, vol.113
, pp. 596-604
-
-
Mackova, N.1
Suliova, J.2
-
25
-
-
68249096784
-
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
-
Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol 2009, 11:973-979.
-
(2009)
Nat. Cell Biol
, vol.11
, pp. 973-979
-
-
Rodier, F.1
Coppe, J.P.2
Patil, C.K.3
Hoeijmakers, W.A.4
Munoz, D.P.5
Raza, S.R.6
-
26
-
-
84902922297
-
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
-
Doloff J.C., Chen C.S., Waxman D.J. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol. Cancer 2014, 13:158.
-
(2014)
Mol. Cancer
, vol.13
, pp. 158
-
-
Doloff, J.C.1
Chen, C.S.2
Waxman, D.J.3
-
27
-
-
0020626585
-
Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis
-
Shih W.W., Baumhefner R.W., Tourtellotte W.W., Haskell C.M., Korn E.L., Fahey J.L. Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin. Exp. Immunol 1983, 53:122-132.
-
(1983)
Clin. Exp. Immunol
, vol.53
, pp. 122-132
-
-
Shih, W.W.1
Baumhefner, R.W.2
Tourtellotte, W.W.3
Haskell, C.M.4
Korn, E.L.5
Fahey, J.L.6
-
29
-
-
0037293242
-
Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen
-
Sefc L., Psenak O., Sykora V., Sulc K., Necas E. Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen. J. Hematother. Stem Cell Res 2003, 12:47-61.
-
(2003)
J. Hematother. Stem Cell Res
, vol.12
, pp. 47-61
-
-
Sefc, L.1
Psenak, O.2
Sykora, V.3
Sulc, K.4
Necas, E.5
-
30
-
-
0019181878
-
Effect of chemotherapeutic agents on natural and BCG-stimulated macrophage cytotoxicity in mice
-
Mantovani A., Luini W., Candiani G.P., Spreafico F. Effect of chemotherapeutic agents on natural and BCG-stimulated macrophage cytotoxicity in mice. Int. J. Immunopharmacol 1980, 2:333-339.
-
(1980)
Int. J. Immunopharmacol
, vol.2
, pp. 333-339
-
-
Mantovani, A.1
Luini, W.2
Candiani, G.P.3
Spreafico, F.4
-
31
-
-
0038792094
-
IL-15 is an essential mediator of peripheral NK-cell homeostasis
-
Ranson T., Vosshenrich C.A., Corcuff E., Richard O., Muller W., Di Santo J.P. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003, 101:4887-4893.
-
(2003)
Blood
, vol.101
, pp. 4887-4893
-
-
Ranson, T.1
Vosshenrich, C.A.2
Corcuff, E.3
Richard, O.4
Muller, W.5
Di Santo, J.P.6
-
32
-
-
0033084021
-
IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor
-
Hyodo Y., Matsui K., Hayashi N., Tsutsui H., Kashiwamura S., Yamauchi H., et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J. Immunol 1999, 162:1662-1668.
-
(1999)
J. Immunol
, vol.162
, pp. 1662-1668
-
-
Hyodo, Y.1
Matsui, K.2
Hayashi, N.3
Tsutsui, H.4
Kashiwamura, S.5
Yamauchi, H.6
-
33
-
-
49649105001
-
Cutting edge: Priming of NK cells by IL-18
-
Chaix J., Tessmer M.S., Hoebe K., Fuseri N., Ryffel B., Dalod M., et al. Cutting edge: Priming of NK cells by IL-18. J. Immunol 2008, 181:1627-1631.
-
(2008)
J. Immunol
, vol.181
, pp. 1627-1631
-
-
Chaix, J.1
Tessmer, M.S.2
Hoebe, K.3
Fuseri, N.4
Ryffel, B.5
Dalod, M.6
-
34
-
-
60549117539
-
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
-
Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med 2009, 206:25-34.
-
(2009)
J. Exp. Med
, vol.206
, pp. 25-34
-
-
Huntington, N.D.1
Legrand, N.2
Alves, N.L.3
Jaron, B.4
Weijer, K.5
Plet, A.6
-
35
-
-
0030265706
-
Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells
-
Oshimi Y., Oda S., Honda Y., Nagata S., Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol 1996, 157:2909-2915.
-
(1996)
J. Immunol
, vol.157
, pp. 2909-2915
-
-
Oshimi, Y.1
Oda, S.2
Honda, Y.3
Nagata, S.4
Miyazaki, S.5
-
36
-
-
0028962125
-
Fas-mediated cytotoxicity by freshly isolated natural killer cells
-
Arase H., Arase N., Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med 1995, 181:1235-1238.
-
(1995)
J. Exp. Med
, vol.181
, pp. 1235-1238
-
-
Arase, H.1
Arase, N.2
Saito, T.3
-
37
-
-
77957157551
-
The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease
-
Karin N. The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J. Leukoc. Biol 2010, 88:463-473.
-
(2010)
J. Leukoc. Biol
, vol.88
, pp. 463-473
-
-
Karin, N.1
-
38
-
-
84872609726
-
Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer
-
Hong X., Dong T., Hu J., Yi T., Li W., Zhang Z., Lin S., Niu W. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int. J. Colorectal Dis 2013, 28:25-33.
-
(2013)
Int. J. Colorectal Dis
, vol.28
, pp. 25-33
-
-
Hong, X.1
Dong, T.2
Hu, J.3
Yi, T.4
Li, W.5
Zhang, Z.6
Lin, S.7
Niu, W.8
-
39
-
-
84887494213
-
Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion
-
Tel J., Sittig S.P., Blom R.A., Cruz L.J., Schreibelt G., Figdor C.G., et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol 2013, 191:5005-5012.
-
(2013)
J. Immunol
, vol.191
, pp. 5005-5012
-
-
Tel, J.1
Sittig, S.P.2
Blom, R.A.3
Cruz, L.J.4
Schreibelt, G.5
Figdor, C.G.6
-
40
-
-
0018142447
-
Induction of macrophage production and proliferation by a purified colony stimulating factor
-
Stanley E.R., Chen D.M., Lin H.S. Induction of macrophage production and proliferation by a purified colony stimulating factor. Nature 1978, 274:168-170.
-
(1978)
Nature
, vol.274
, pp. 168-170
-
-
Stanley, E.R.1
Chen, D.M.2
Lin, H.S.3
-
41
-
-
0027407109
-
Endothelial-leukocyte adhesion molecules
-
Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol 1993, 11:767-804.
-
(1993)
Annu. Rev. Immunol
, vol.11
, pp. 767-804
-
-
Bevilacqua, M.P.1
-
42
-
-
0035514524
-
Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration
-
Radi Z.A., Kehrli M.E., Ackermann M.R. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J. Vet. Intern. Med 2001, 15:516-529.
-
(2001)
J. Vet. Intern. Med
, vol.15
, pp. 516-529
-
-
Radi, Z.A.1
Kehrli, M.E.2
Ackermann, M.R.3
-
43
-
-
7144264398
-
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
-
Detmar M., Brown L.F., Schon M.P., Elicker B.M., Velasco P., Richard L., et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol 1998, 111:1-6.
-
(1998)
J. Invest. Dermatol
, vol.111
, pp. 1-6
-
-
Detmar, M.1
Brown, L.F.2
Schon, M.P.3
Elicker, B.M.4
Velasco, P.5
Richard, L.6
-
44
-
-
0027197245
-
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
-
Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
-
(1993)
Nature
, vol.362
, pp. 841-844
-
-
Kim, K.J.1
Li, B.2
Winer, J.3
Armanini, M.4
Gillett, N.5
Phillips, H.S.6
-
45
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med 1995, 1:27-31.
-
(1995)
Nat. Med
, vol.1
, pp. 27-31
-
-
Folkman, J.1
-
46
-
-
80053159303
-
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
-
Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol 2011, 11:702-711.
-
(2011)
Nat. Rev. Immunol
, vol.11
, pp. 702-711
-
-
Motz, G.T.1
Coukos, G.2
-
47
-
-
34047131797
-
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
-
Johnson B.F., Clay T.M., Hobeika A.C., Lyerly H.K., Morse M.A. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin. Biol. Ther 2007, 7:449-460.
-
(2007)
Expert Opin. Biol. Ther
, vol.7
, pp. 449-460
-
-
Johnson, B.F.1
Clay, T.M.2
Hobeika, A.C.3
Lyerly, H.K.4
Morse, M.A.5
-
48
-
-
54249133961
-
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands
-
Wendel M., Galani I.E., Suri-Payer E., Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008, 68:8437-8445.
-
(2008)
Cancer Res
, vol.68
, pp. 8437-8445
-
-
Wendel, M.1
Galani, I.E.2
Suri-Payer, E.3
Cerwenka, A.4
-
49
-
-
0037943965
-
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor
-
Ferrari S., Rovati B., Porta C., Alessandrino P.E., Bertolini A., Collova E., et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol. Immunother 2003, 52:359-366.
-
(2003)
Cancer Immunol. Immunother
, vol.52
, pp. 359-366
-
-
Ferrari, S.1
Rovati, B.2
Porta, C.3
Alessandrino, P.E.4
Bertolini, A.5
Collova, E.6
-
50
-
-
70350108862
-
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
-
Radojcic V., Bezak K.B., Skarica M., Pletneva M.A., Yoshimura K., Schulick R.D., et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother 2010, 59:137-148.
-
(2010)
Cancer Immunol. Immunother
, vol.59
, pp. 137-148
-
-
Radojcic, V.1
Bezak, K.B.2
Skarica, M.3
Pletneva, M.A.4
Yoshimura, K.5
Schulick, R.D.6
-
51
-
-
84862980672
-
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
-
Martin-Padura I., Marighetti P., Agliano A., Colombo F., Larzabal L., Redrado M., et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest 2012, 92:952-966.
-
(2012)
Lab. Invest
, vol.92
, pp. 952-966
-
-
Martin-Padura, I.1
Marighetti, P.2
Agliano, A.3
Colombo, F.4
Larzabal, L.5
Redrado, M.6
-
52
-
-
45949087412
-
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts
-
Shahrzad S., Shirasawa S., Sasazuki T., Rak J.W., Coomber B.L. Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene 2008, 27:3729-3738.
-
(2008)
Oncogene
, vol.27
, pp. 3729-3738
-
-
Shahrzad, S.1
Shirasawa, S.2
Sasazuki, T.3
Rak, J.W.4
Coomber, B.L.5
-
53
-
-
84874753845
-
A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy
-
Kubisch R., Meissner L., Krebs S., Blum H., Gunther M., Roidl A., et al. A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl. Oncol 2013, 6:1-9.
-
(2013)
Transl. Oncol
, vol.6
, pp. 1-9
-
-
Kubisch, R.1
Meissner, L.2
Krebs, S.3
Blum, H.4
Gunther, M.5
Roidl, A.6
-
54
-
-
77950916340
-
In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
-
Thoenes L., Hoehn M., Kashirin R., Ogris M., Arnold G.J., Wagner E., et al. In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J. Proteomics 2010, 73:1342-1354.
-
(2010)
J. Proteomics
, vol.73
, pp. 1342-1354
-
-
Thoenes, L.1
Hoehn, M.2
Kashirin, R.3
Ogris, M.4
Arnold, G.J.5
Wagner, E.6
-
55
-
-
78650991789
-
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
-
Emmenegger U., Francia G., Chow A., Shaked Y., Kouri A., Man S., et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011, 13:40-48.
-
(2011)
Neoplasia
, vol.13
, pp. 40-48
-
-
Emmenegger, U.1
Francia, G.2
Chow, A.3
Shaked, Y.4
Kouri, A.5
Man, S.6
-
56
-
-
46749156706
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
-
Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest 2008, 118:2609-2619.
-
(2008)
J. Clin. Invest
, vol.118
, pp. 2609-2619
-
-
Guix, M.1
Faber, A.C.2
Wang, S.E.3
Olivares, M.G.4
Song, Y.5
Qu, S.6
-
57
-
-
21744437791
-
Repopulation of cancer cells during therapy: an important cause of treatment failure
-
Kim J.J., Tannock I.F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 2005, 5:516-525.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 516-525
-
-
Kim, J.J.1
Tannock, I.F.2
-
58
-
-
65649087840
-
A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance
-
O'Connor R. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr. Cancer Drug Targets 2009, 9:273-280.
-
(2009)
Curr. Cancer Drug Targets
, vol.9
, pp. 273-280
-
-
O'Connor, R.1
-
59
-
-
33751300540
-
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide
-
Moreb J.S., Mohuczy D., Ostmark B., Zucali J.R. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother. Pharmacol 2007, 59:127-136.
-
(2007)
Cancer Chemother. Pharmacol
, vol.59
, pp. 127-136
-
-
Moreb, J.S.1
Mohuczy, D.2
Ostmark, B.3
Zucali, J.R.4
|